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doi: 10.1016/j.exphIn order to develop minimally toxic bone marrow transplantation (BMT) protocols suitable
for use in a wider range of indications, it is important to identify ways to enhance BM engraft-
ment at a given level of recipient conditioning. CXCL12/stromal cell-derived factor-1a plays
a crucial physiological role in homing of hematopoietic stem cells to BM. It is regulated by the
ectopeptidase dipeptidyl peptidase IV (DPPIV; DPP4) known as CD26, which cleaves dipep-
tides from the N-terminus of polypeptide chains. Blocking DPPIV enzymatic activity had
a beneficial effect on hematopoietic stem cell engraftment in various but very specific exper-
imental settings. Here we investigated whether inhibition of DPPIV enzymatic activity
through Diprotin A or sitagliptin (Januvia) improves BM engraftment in nonmyeloablative
murine models of syngeneic (i.e., CD45-congenic) and allogeneic (i.e., Balb/c to B6) BMT
(1 Gy total body irradiation, 10–15 3 106 unseparated BM cells/mouse). Neither Diprotin
A administered in vivo at the time of BMT and/or used for in vitro pretreatment of BM
nor sitagliptin administered in vivo had a detectable effect on the level of multilineage chime-
rism (follow-upO20 weeks). Similarly, sitagliptin did not enhance chimerism after allogeneic
BMT, even though DPPIV enzymatic activity measured in serum was profoundly inhibited
(O98% inhibition at peak exposure). Our results provide evidence that DPPIV inhibition
via Diprotin A or sitagliptin does not improve engraftment of unseparated BM in a nonmye-
loablative BMT setting.  2012 ISEH - Society for Hematology and Stem Cells. Published
by Elsevier Inc.Allogeneic bone marrow transplantation (BMT) has thera-
peutic potential for a wide range of indications. Its clinical
application remains limited mainly to the treatment of
life-threatening diseases because of substantial toxicities
associated with currently available BMT regimens.
Transplantation of donor BM to induce mixed hema-
topoietic chimerism is an attractive experimental
approach to induce robust and lasting donor-specific
tolerance in organ transplantation [1]. The clinical rele-
vance of this tolerance strategy has recently been und-
erscored by a pilot trial in which patients suffering from: Thomas Wekerle, M.D., Division of Transplanta-
rgery, Vienna General Hospital, Waehringer Guertel
tria; E-mail: Thomas.Wekerle@meduniwien.ac.at
nt matter. Copyright  2012 ISEH - Society for Hematolo
em.2011.10.010end-stage renal disease simultaneously received a kidney
and BM graft from a human leukocyte antigen–mismatched
living related donor [2,3]. Most recipients in this small
study became operationally tolerant. However, the non-
myeloablative conditioning regimen was associated with
substantial side effects, such as profound leukopenia,
rendering this regimen virtually unacceptable in the
routine organ transplantation setting. Therefore, less toxic
BMT regimens achieving sufficient engraftment with
reduced myelosuppressive conditioning still need to be
developed to allow a more widespread application of
this strategy [4].
In the experimental setting, less toxic mixed chimerism
protocols have been generated gradually during the last
several decades. The use of costimulatory blockersdsome
of which are already under clinical development asgy and Stem Cells. Published by Elsevier Inc.
Table 1. Experimental protocols
Group TBI HSCT (cells/mouse) CB Additional treatment Mouse strain
A 1 15  106 BMC  - Congenic
B 1 15  106 BMC  5 mM Diprotin A in vitro (15 min) Congenic
C 1 10  106 BMC  - Congenic
D 1 10  106 BMC  5 mM Diprotin A in vitro (15 min) & in vivo
(4 mM Diprotin A with BMiv & 5 mM
Diprotin A sc 2/day)
(72h) Congenic
E 1 10  106 BMC  Sitagliptin in vivo (4 mg/mouse/2/day) (72h) Congenic
F 1 15  106 BMC þ - Allogenic
G 1 15  106 BMC þ Sitagliptin in vivo (4 mg/mouse/2/day) (48h) Allogenic
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has allowed us to further reduce conditioning substantially
[7–11]. Short-course rapamycin [12,13] and therapeutic
administration of regulatory T cells [1,14] have led to the
most advanced murine minimum conditioning protocols.
However, translation to nonhuman primate models has re-
vealed that only transient chimerism is achieved with proto-
cols that establish permanent chimerism in mice [15,16].
Development of adjunctive treatments capable of pro-
moting engraftment of a given dose of BM at a certain level
of recipient myelosuppression is a critical goal toward clin-
ical translation of the mixed chimerism approach.
The chemoattractant stromal cell–derived factor-1
(CXCL12) binding to CXCR4 on hematopoietic stem cells
(HSCs) plays an important role in regulating trafficking of
HSCs to BM [17]. Dipeptidylpeptidase IV (DPPIV/CD26)
is an ectopeptidase that cleaves stromal cell–derived
factor-1 and thereby abrogates its chemotactic function
[18] with the consequence of reduced homing of HSCs to
their BM niches [19,20]. Specific inhibition of DPPIV/
CD26 via Diprotin A, an enzymatic inhibitor consisting
of three amino acids (Ile-Pro-Ile), enhanced BM engraft-
ment in certain murine BMT models [21–25]. Notably,
Christopherson et al. showed a benefit on engraftment
when BM was incubated with Diprotin A before trans-
plantation into myeloablated congenic recipients [20].
Combining in vivo with in vitro treatment with Diprotin A
was found to further enhance its efficacy [24]. However, it
remains undetermined whether DPPIV/CD26 inhibition
promotes engraftment of unseparated BM in the nonmye-
loablative mixed chimerism setting.
An immunosuppressive role of DPPIV inhibition has also
been suggested in organ transplantationmodels (not involving
BMT), as an irreversible inhibitor of DPPIV abrogated acute
rejection in rat lung and heart transplantation models
[26,27] and reduced ischemia/reperfusion injury [28]. This
effect may be due to DPPIV/CD26-mediated truncation of
mediators (such as cytokines and chemokines) [29,30], to
a potential costimulatory function of CD26, or to so far
unknown off-target effects of the inhibitor used [31–34].
We report that neither in vitro DPPIV/CD26 enzymatic
inhibition of donor BM using Diprotin A nor additional
systemic inhibition led to enhanced BM engraftment ina congenic murine model using 1 Gy total body irradiation
(TBI) and conventional doses of BM. Moreover, we provide
evidence that the clinically approved DPPIV inhibitor sita-
gliptin [35] completely blocked DPPIV/CD26 enzymatic
activity in vivo, but nevertheless did not increase BM
engraftment in either allogeneic or congenic models of non-
myeloablative BMT.Materials and methods
Animals
Female C57BL/6NCrl (H-2b, CD45.2, denoted B6 herein), Balb/c
(H-2d), and C3H/N (H-2k) were purchased from Charles River
Laboratories (Sulzfeld, Germany), female B6.SJL-Ptprca Pep3b/
BoyJ mice (H-2b, CD45.1, denoted CD45.1 B6 herein) were
purchased from the Jackson Laboratory (Bar Harbour, ME,
USA). All mice were housed under specific pathogen-free condi-
tions and were used between 6 and 12 weeks of age. All experi-
ments were approved by the local review board of the Medical
University of Vienna, and were performed in accordance with
national and international guidelines of laboratory animal care.
BMT protocol
Treatment protocols per group are listed in Table 1. For the con-
genic setting (groups A through E) CD45.1 B6 were used as recip-
ients and B6 (i.e., CD45.2) as donors. For the allogeneic setting
(groups F and G) B6 were used as recipients, Balb/c as donors
and C3H as third party. Recipients received 1 Gy TBI (day –1)
and either 10  106 or 15  106 unseparated congenic or alloge-
neic BM cells (day 0), as indicated. Allogeneic recipients received
costimulation blockade consisting of anti-CD154 monoclonal
antibody (MR1, 1 mg, day 0), and hCTLA4Ig (abatacept, 0.5 mg,
day 2) [12]. Indicated groups of mice received the following DPPIV
inhibition regimens. BM in vitro pretreated with Diprotin A
(group B); BM in vitro pretreated with Diprotin A plus in vivo
recipient treatment with Diprotin A (group D); in vivo recipient
treatment with sitagliptin (group E and G). Groups A, C, and F
served as controls without DPPIV inhibition. Anti-CD154 mono-
clonal antibody was purchased from BioXCell (West Lebanon,
NH, USA), hCTLA4Ig (abatacept) was generously provided by
Bristol-Myers, Squibb Pharmaceuticals (Princeton, NJ, USA).
DPPIV inhibition
Donor BM was harvested, washed, and resuspended in BM
medium containing M199 (Sigma M 4530), DNAse (Sigma
D-4527), gentamycin, and HEPES (1M) as described [12,36]. The
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pretreatment of BM with Diprotin A (groups B, D) was performed
by incubating BM with a concentration of 5 mM Diprotin A for 15
min at room temperature [22] (group B) or for 15 min at 37C [21]
(group D). Subsequently, bone marrow cells (BMC) were washed
in BM medium, counted, and resuspended. For in vivo recipient
treatment with Diprotin A (group D), BMC were resuspended in
1 mL BM medium containing 4 mmol Diprotin A, which was in-
jected intravenously and 100 mL phosphate-buffered saline con-
taining 5 mmol Diprotin A injected subcutaneously every 12
hours for 3 days (days 0, 1, and 2). This daily dose of Diprotin
A was chosen as it showed therapeutic effects in other murine
models [37,38]. For in vivo recipient treatment with sitagliptin
(groups E and G), sitagliptin tablets (100 mg) were suspended
in 2 mL cold phosphate-buffered saline under aseptic conditions,
resulting in 4 mg/80 mL. Four milligrams sitagliptin was adminis-
tered by oral gavage every 12 hours on days 0 and 1 (group G) or
on days 0, 1, and 2 (group E) post-BMT. Diprotin Awas purchased
from Sigma Aldrich and sitagliptin (Januvia) was kindly provided
by Merck (Vienna, Austria).
Assay for DPPIV activity
DPPIV enzymatic activity was assayed by using glycyl-prolyl-4-
methoxy-b-naphthylamide (Gly-Pro-4-Me-b-NA) as fluorogenic
substrate as described previously [39,40]. In a 96-well plate,
5 mL serum samples were mixed with 0.5 mM Gly-Pro-4-Me-b-
NA in 50 mM Tris buffer (pH 8.3) in a final volume of 110 mL.
DPPIV activity was determined kinetically during 5 min at 37C
by measuring the velocities of 4-Me-b-NA release (lex 5 340 nm,
lem 5 430 nm) from the substrate using an Infinite 200 (Tecan
Group Ltd., Switzerland) (all reagents were purchased from
Sigma-Aldrich). Fluorescence intensity was related to a 4-Me-b-
NA standard curve. The reversibility of the inhibitors in the serum
samples and the dilution of these samples in the assay make it
necessary to create a calibration curve with known concentrations
of the inhibitors in murine serum to estimate the percentage
in vivo inhibition of DPPIV enzymatic activity in the serum.
Percentage inhibition was calculated by comparing DPPIV enzy-
matic activity of treated mice to control mice, which were not
enzymatically inhibited (defined as 100% activity). In order to
limit the number of blood draws per mouse, groups were split in
two and blood was taken only once a day for each mouse (either
at 2 hours or 12 hours post–DPPIV inhibitor administration).
Flow cytometric analysis
Two-color flow cytometric analysis was used to distinguish donor
and recipient cells of particular lineages by staining with fluores-
cein isothiocyanate–conjugated antibodies against CD4, CD8,
B220, MAC-1, and biotinylated CD45.2 or 34-2-12 (H-2Dd, de-
tected with phycoerythrin-streptavidin) and irrelevant isotype
controls [12,36]. Propidium iodide staining was used to exclude
dead cells. The net percentage of CD45.2þ or 34-2-12þ live cells
among different cell lineages was calculated. Mice were consid-
ered chimeric if they demonstrated at least 2% of donor cells
within the myeloid lineage plus at least one lymphoid lineage.
Surface staining was performed according to standard procedures
and flow cytometric analysis was done on a Coulter Cytomics
FC500. CXP software (Coulter, Vienna, Austria) was used for
acquisition and analysis. Antibodies were purchased from Becton
Dickinson (San Diego, CA, USA).Skin grafting
Full-thickness tail skin from Balb/c mice and fully mismatched
C3H (third party) was grafted 2 to 8 weeks after allogeneic
BMT and visually inspected thereafter at short intervals. Grafts
were considered rejected when !10% remained viable.
Statistics
A two-sided Student’s t test was used to compare chimerism levels
between the groups. Skin graft survival was calculated according
to the Kaplan–Meier product limit method and compared between
groups using the log-rank test.Results
Inhibition of DPPIV with Diprotin A does not improve
engraftment of unseparated congenic BM after
nonmyeloablative conditioning
To investigate the effect of DPPIV inhibition on the engraft-
ment of unseparated BM in the absence of alloreactivity, we
first used a CD45.2 / CD45.1 congenic donor-recipient
combination [36,41]. CD45.1 B6 mice conditioned with 1
Gy TBI received 15  106 unseparated CD45.2 BMCs
that were or were not pretreated in vitro with the DPPIV
inhibitor Diprotin A (n 5 9/group) [22]. Multilineage
chimerism was followed in blood by flow cytometry.
Lasting chimerism developed in all mice in both groups.
During a period of 21 weeks post-BMT, chimerism levels
were comparable between Diprotin A–pretreated (group
B) and nontreated (group A) groups in all tested lineages
at all analyzed time points (note: treated and nontreated
groups were done in parallel within one experiment to
allow optimal comparability) (Fig. 1A). At the end of
follow-up, mean percentages (6standard deviation) of
chimerism were 35.7% (67.0%) vs 39.9% (67.7%) among
CD4 cells, 23.0% (64.7%) vs 29.3% (69.1%) among CD8
cells, 40.6% (610.7%) vs 51.3% (613.4%) among B cells,
and 26.7% (610.2%) vs 39.5% (614.9%) among myeloid
cells (Diprotin A pretreatment vs control group; p 5 NS for
all lineages). Similarly, there were no differences in chime-
rism levels between groups in BM and spleen (p 5 NS,
Fig. 1B).
Because a beneficial effect has been described when
in vitro Diprotin A pretreatment of donor BM was
combined with in vivo recipient treatment with Diprotin A
[24], we tested whether such a combination regimen would
impact engraftment in the nonmyeloablative congenic
setting (group D). In addition to in vitro pretreatment of
the BM, Diprotin A was injected in vivo together with the
BM and every 12 hours thereafter for 3 days post-BMT
(n 5 5). Again, chimerism levels were similar with (group
D) and without (group C) DPPIV inhibition at all tested
time points (follow-up 22 weeks; p 5 NS for all time
points) (Fig. 2A). At the end of follow-up, mean percent-
ages of chimerism were 50.5% (65.8%) vs 43.7% (66.4%)
among CD4 cells, 36.4% (64.7%) vs 29.3% (66.5%)
Figure 1. Chimerism following transplantation of congenic BMCs pretreated in vitro with Diprotin A. Recipient mice were conditioned with 1 Gy TBI and
received 15  106 congenic CD45.2 BMCs (n 5 9/control group A, n 5 9/Diprotin A–treated group B). BMCs of group B were treated in vitro with 5 mM
Diprotin A before transplantation. The levels of chimerism in blood over time (A), was determined by flow cytometry and is presented as means for Diprotin
A–treated (squares) and untreated (dotted line with diamonds) groups. In (B) chimerism in BM and spleen at the end of follow-up is depicted in box and
whisker plots. No significant differences were noted between both groups.
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Figure 2. Chimerism after transplantation of congenic BMCs after combined treatment with Diprotin A in vitro and in vivo and after in vivo treatment with
sitagliptin. Recipient mice were conditioned with 1 Gy TBI and received 10  106 congenic CD45.2 BMCs (n5 6/control group C, n5 5/Diprotin A–treated
group D, n 5 7/sitagliptin-treated group E). In group D, BMC were treated in vitro with 5 mM Diprotin A before transplantation and, in addition, recipients
were treated in vivo with Diprotin A (4 mmol IV day 0 and 5 mmol Diprotin A subcutaneously every 12 hours for 3 days). Recipients of group E were treated
with sitagliptin orally. Levels of chimerism in blood over time (A) were determined by flow cytometry and are presented as means for Diprotin A–treated
(squares), sitagliptin-treated (dotted line with triangle) and untreated (dotted line with diamonds) groups. In (B) chimerism in BM and spleen at the end of
follow-up is depicted in box and whisker plots. No significant differences were noted between both groups.
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among B cells, and 54.2% (610.0%) vs 41.6% (611.5%)
among myeloid cells. Chimerism levels in BM and spleen
were also comparable among groups.Collectively, these experiments demonstrate that DPPIV
inhibition with Diprotin A does not lead to a detectable
improvement of the engraftment of unseparated congenic
BM in nonmyeloablatively conditioned recipients.
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effectively than Diprotin A
To assess whether the failure to detect an engraftment effect
is due to insufficient DPPIV inhibition achieved with in vivo
Diprotin A treatment, serum DPPIVactivity was measured.
At peak exposure (2 hours after administration of Dipro-
tin A, group D), DPPIV serum activity decreased to 78.1%
and 55.1% in two (randomly selected) mice, whereas
DPPIV activity remained essentially unchanged in one
mouse (Fig. 3A). At the time of trough exposure (12 hours
postadministration), enzymatic activity declined to 51.7%,
47.1%, and 16.1% in three remaining mice of the group
(Fig. 3A). Thus, although Diprotin A inhibits DPPIV
activity, inhibition is only moderate.
Sitagliptin (Januvia) is a specific DPPIV inhibitor that
has recently been approved for the treatment of type 2 dia-
betes [42]. We hypothesized that a more complete (and
clinically relevant) inhibition of DPPIV may be achieved
with this drug. Sitagliptin has a half-life of about 12 to
14 hours [43] and is administered once daily at a dose of
100 mg (i.e., roughly 1.3 mg/kg) in the clinical setting of
type 2 diabetes. We measured DPPIV activity in serum of
mice treated with 4 mg sitagliptin orally every 12 hours
(160 mg/kg twice daily) (group E). Complete inhibition
of DPPIV enzymatic activity at peak exposure (2 hours
postadministration) was observed in all four tested mice
(0.7%, 0.4%, 0.5%, and 0.5% enzymatic activity)
(Fig. 3B). At trough level 12 hours after the last dose, enzy-
matic DPPIV activity decreased to a mean of 31.9% (i.e.,
68% inhibition) (16.2%, 22.1%, 57.4% in the remaining
three mice of the group) (Fig. 3B). Thus, in vivo treatment
with sitagliptin leads to more effective inhibition of DPPIV
activity at peak exposure than Diprotin A. However, with
neither compound, a complete DPPIV inhibition for the
entire treatment period was achieved, as moderate enzy-
matic activity at trough levels could still be observed.
Despite superior DPPIV inhibition, sitagliptin does not
improve engraftment of unseparated congenic BMT after
nonmyeloablative conditioning
To assess whether sitagliptin affects engraftment, we followed
hematopoietic chimerism in sitagliptin-treated recipients of
unseparated congenicBM(n5 7, groupE).Again, no enhanced
engraftment was detected on DPPIV inhibition (p 5 NS at all
time points). Twenty-two weeks post-BMT mean chimerism
levels were 48.8% (65.7%) vs 43.7% (66.4%) among CD4
cells, 34.5% (63.0%) vs 29.3% (66.5%) among CD8 cells,
60.1% (69.8%) vs 54.9% (69.5%) among B cells, and 48.6%
(611.1%) vs 41.6% (611.5%) among myeloid cells (treated
group E vs control group C) (Fig. 2A). Chimerism levels in
BM and spleen (Fig. 2B) were also comparable (p 5 NS).
Thus, with the more specific, clinically approved DPPIV
inhibitor sitagliptin, no beneficial effect was detectable on the
engraftment of congenic BM in nonmyeloablated recipient
mice.Sitagliptin does not improve engraftment in a mixed
chimerism model of allogeneic BMT with
nonmyeloablative conditioning and costimulation
blockade
DPPIV inhibition was shown to affect alloreactivity in
models of heart and lung transplantation [26,27]. As little
is known, however, about the effect of DPPIV inhibitors
in allogeneic BMT, we tested whether sitagliptin may
improve engraftment in an allogeneic mixed chimerism
model of limiting conditioning. B6 mice conditioned with
1 Gy TBI (day –1), were transplanted with 15  106 fully
mismatched Balb/c BMCs (day 0), and treated with anti-
CD154 monoclonal antibody (day 0) and CTLA4Ig (day
þ2), as described previously [12]. This BMT regimen is
insufficient to induce reliable chimerism (and tolerance)
by itself, but chimerism and tolerance can be achieved
through adjunctive treatments, such as rapamycin [12].
One group was treated with sitagliptin orally (group G,
n 5 6) and was compared to one left untreated (group F,
n 5 6).
Again, sitagliptin nearly completely inhibited DPPIV
enzymatic activity after 2 hours (0.9%, 1.0%, 1.0%,
1.8%) and activity remained substantially decreased in 2
of 4 mice (32.2%, 32.5%, 81.4%, O85%) after 12 hours
(Fig. 3C). As expected, without sitagliptin, mean chimerism
levels were low with varying individual levels and several
mice had no detectable T-cell chimerism at the end of
follow-up (Fig. 4A). Sitagliptin treatment, however, did
not improve chimerism levels. Chimeric mice (six of seven
chimeras in the sitagliptin-treated group vs five of six in the
control group) showed chimerism levels of 1.6% (61.1%)
vs 1.8% (62.5%) among CD4 cells, 0.4% (60.6%) vs
3.5% (63.1%) among CD8 cells, 7.5% (63.8%) vs 8.8%
(64.1%) among B cells, and 16.6% (612.5%) vs 21.8%
(610.3%) among myeloid cells for each lineage (p 5
NS). Similarly, chimerism levels and rates were also
comparable between groups in spleen (Fig. 4B).
Donor and third-party skin was transplanted to assess
donor-specific tolerance. Third-party grafts were promptly
rejected in both groups. Donor skin graft survival was
significantly prolonged in both groups but tolerance was
not achieved, consistent with the poor T-cell chimerism
(p 5 0.5 sitagliptin-treated vs untreated recipients) [8,44].
Taken together, these results indicate that sitagliptin
does not improve engraftment of allogeneic BM under
limiting recipient conditioning and consequently does not
improve tolerance induction in this setting.Discussion
Induction of donor-specific transplantation tolerance
through mixed chimerism would be a potential new indica-
tion for allogeneic BMT. During the last 2 decades, the
toxicity of the recipient conditioning was gradually reduced
in murine chimerism models [1]. Nevertheless cytotoxic
Figure 3. DPPIVenzymatic activity in serum after in vivo inhibition with Diprotin A or sitagliptin. DPPIVenzymatic activity in serum was measured 2 (peak)
and 12 hours (trough) after in vivo treatmentwithDiprotinA (groupD) or sitagliptin (group E). DPPIVenzymatic activity at peak and trough exposure is depicted
for Diprotin A– (A) and sitagliptin-treated [(B) congenic, (C) allogeneic model] groups (n 5 3–4 randomly selected mice per group, congenic BMT).
103E. Schwaiger et al./ Experimental Hematology 2012;40:97–106conditioning used to achieve engraftment of clinically
feasible numbers of BMCs keeps impeding clinical transla-
tion of such protocols. Minimally toxic BMT regimens
would also be of interest to allow other potential indications
of BMT [9].Inhibition or genetic ablation of DPPIV/CD26 showed
promising engraftment-promoting effects in several murine
models especially when limited numbers of donor cells
were used [25]. DPPIV enzymatic activity inhibition was
effective in congenic (CD45-congenic) [20,38], xenogeneic
Figure 4. Chimerism and skin graft survival following transplantation of allogeneic BMCs after in vivo treatment with sitagliptin. Recipient mice were trans-
planted with 15  106 allogeneic BMCs after 1 Gy TBI (day –1) and costimulation blockade consisting of anti CD-154 monoclonal antibody (day 0) and
CTLA4Ig (day 2). Four milligrams sitagliptin per mouse were administered twice a day (day 0–2). (A) Mean percent of blood chimerism among different cell
lineages over time are depicted for sitagliptin-treated (bold lines with squares) and untreated (dotted lines with triangles) groups. No significant differences
were noted between both groups. (B) Chimerism in spleen was similar in both groups at the end of follow-up. (C) Approximately 8 weeks post-BMT, mice
were grafted with donor and third-party skin. Skin graft survival was comparable in both groups (p 5 0.5).
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immune-deficient recipients) [23,25], and allogeneic (major
histocompatibility complex–mismatched in utero transplan-tation) [22] systems. Engraftment-enhancing effects of
DPPIV inhibition were not only observed with separated
(Sca1þlin murine BMCs or CD34þ human mobilized
105E. Schwaiger et al./ Experimental Hematology 2012;40:97–106peripheral blood/cord blood cells, respectively) [20,24,25],
but also with unseparated populations [20,22,38]. We
therefore chose nonmyeloablative protocols using unsepa-
rated BMCs for evaluating DPPIV enzymatic inhibition,
as such systems are commonly used in the clinical setting
(but to the best of our knowledge have not been studied
in the DPPIV inhibition context before). In addition, we tar-
geted DPPIV in a fully allogeneic model, which would be
similar to the clinical situation of tolerance induction in
organ transplantation. In these settings, we did not detect
a significant effect of DPPIV enzymatic activity inhibition
on BM engraftment (despite using Diprotin A treatment
schedules proven effective in other settings).
In order to dissect whether a potential effect of DPPIV
inhibition is due to modulating alloreactivity or HSC
engraftment, we used two established models of nonmye-
loablative BMT. The CD45.2 / CD45.1 congenic model
is almost free of relevant immunological barriers [36,41].
In the 1-Gy allogeneic protocol, immunosuppressiond
through rapamycin [12] or administration of T regulatory
cells [45]dleads to engraftment and lasting chimerism in
this otherwise unsuccessful BMT protocol.
Several DPPIV inhibitors have recently been approved for
treatment of type 2 diabetes. We therefore tested whether si-
tagliptin enhances the engraftment of congenic or allogeneic
BMafter nonmyeloablative TBI. As compared toDiprotinA,
sitagliptin is both a more potent and specific DPPIV inhibitor
[46] that would be of importance for translating experimental
results to the clinical setting. Despite inhibition of DPPIV
enzymatic serum activity, no beneficial effect of sitagliptin
was detectable in our studies.
Maximum inhibition of DPPIV serum activity (measured
2 hours after in vivo administration) was more profound with
sitagliptindachieving almost 100% inhibitiondthan with
Diprotin A (Fig. 3). A rapid recovery of DPPIV systemic
activity after Diprotin A treatment was also noted by Christo-
pherson and colleagues [20], but this transient inhibition was
nevertheless sufficient to positively affect engraftment in the
myeloablative setting. Kim and colleagues reported prolon-
gation of islet graft survival with sitagliptin [47]. Sitagliptin
was given in chow with a sitagliptin uptake of roughly 10
mgd48 mg per day resulting in 78% to 88% DPPIV inhibi-
tion. Notably, almost the full inhibitory effect was observed
evenwith the lowest consumeddose of 10mg (approximately
78% inhibition). In the clinical setting of type 2 diabetes, si-
tagliptin is administered once daily, as it has a half-life of
about 12 to 14 hours [43]. We therefore reasoned that oral
administration every 12 hours (at a dose of 160 mg/kg twice
daily compared to the clinical dose of approximately 1.3 mg/
kg/day) would result in sufficient drug exposure during the
critical period of HSC engraftment. It seems unlikely that
the degree or duration of DPPIV inhibition is responsible
for the lack of a detectable engraftment effect in our models.
We think that several factors might be responsible for the
lack of an effect of DPPIV inhibition in our present study.Models in which an engraftment-enhancing of DPPIVinhibi-
tion was found used either myeloablative conditioning or
nonmyeloablative conditioning of immunodeficient recipi-
ents [20,21,23–25,38]. To the best of our knowledge, our
studies are the first to investigate the effect of DPPIV inhibi-
tion on BM engraftment in nonmyeloablatively conditioned
wild-type recipients. In the environment of this different
conditioning regimen, DPPIV inhibition might be unable to
affect engraftment. Furthermore, an engraftment-enhancing
effect of DPPIV inhibition on allogeneic HSC has been
shown so far only aftermyeloablative conditioning or in utero
transplantation [21,22]. The potential effect on allogeneic
BM engraftment after nonmyeloablative conditioningd
which is of relevance for clinical BMTdhas not been ascer-
tained previously. Our results suggest that DPPIV inhibition
is of limited therapeutic value in this setting. Besides, the
current study is the first to investigate the use of costimulation
blockade together with DPPIV inhibition. Although an inter-
action cannot be ruled out, such interferencewould be unable
to explain the observed lack of an effect in the congenic
system, in which no costimulation blockade was used.
In summary, although DPPIV enzymatic inhibition had
been demonstrated to have engraftment-promoting effects
in several specific models of HSC transplantation, our
studies provide evidence that DPPIV inhibition with Dipro-
tin A or with sitagliptin does not lead to improved engraft-
ment of unseparated BM after nonmyeloablative recipient
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